Prednisolone

Prednisolone (Tablets IP 5mg/10mg/40mg) is an intermediate-acting synthetic glucocorticoid with four times the anti-inflammatory potency of hydrocortisone and minimal mineralocorticoid activity, on the WHO Model List of Essential Medicines. It diffuses across cell membranes and binds intracellular glucocorticoid receptors, inhibiting NF-kB, downregulating phospholipase A2, and potently suppressing synthesis of prostaglandins, leukotrienes, and pro-inflammatory cytokines. Indicated for severe autoimmune disorders (systemic lupus erythematosus, rheumatoid arthritis), acute asthma exacerbations, nephrotic syndrome, severe allergic reactions, inflammatory bowel disease, and immunosuppressive therapy.

Prednisolone (Tablets IP 5mg/10mg/40mg) is an intermediate-acting synthetic glucocorticoid with four times the anti-inflammatory potency of hydrocortisone and minimal mineralocorticoid activity, on the WHO Model List of Essential Medicines. It diffuses across cell membranes and binds intracellular glucocorticoid receptors, inhibiting NF-kB, downregulating phospholipase A2, and potently suppressing synthesis of prostaglandins, leukotrienes, and pro-inflammatory cytokines. Indicated for severe autoimmune disorders (systemic lupus erythematosus, rheumatoid arthritis), acute asthma exacerbations, nephrotic syndrome, severe allergic reactions, inflammatory bowel disease, and immunosuppressive therapy.

Prednisolone Acetate / Sodium Phosphate (1% w/v eye drops) is the gold-standard topical ophthalmic corticosteroid on the WHO Model List of Essential Medicines. It delivers high corneal and intraocular penetration, suppressing cellular infiltration, capillary dilatation, fibroblast proliferation, and collagen deposition in the anterior segment. Indicated for steroid-responsive ocular inflammation (anterior uveitis, post-operative cataract inflammation, severe allergic blepharoconjunctivitis, and corneal graft rejection prophylaxis).

Prednisolone Acetate / Sodium Phosphate (1% w/v eye drops) is the gold-standard topical ophthalmic corticosteroid on the WHO Model List of Essential Medicines. It delivers high corneal and intraocular penetration, suppressing cellular infiltration, capillary dilatation, fibroblast proliferation, and collagen deposition in the anterior segment. Indicated for steroid-responsive ocular inflammation (anterior uveitis, post-operative cataract inflammation, severe allergic blepharoconjunctivitis, and corneal graft rejection prophylaxis).

Moxifloxacin and Corticosteroid (Dexamethasone 0.1% or Prednisolone 1%) ophthalmic drops is a broad-spectrum anti-infective and potent anti-inflammatory combination. Moxifloxacin (0.5%), a 4th-generation fluoroquinolone, inhibits bacterial DNA gyrase and topoisomerase IV across Gram-positive, Gram-negative, and atypical pathogens, while the steroid suppresses ocular surgical trauma, anterior chamber inflammation, and corneal edema. Indicated for post-operative prevention and treatment of inflammation and infection following cataract, refractive, or vitreoretinal surgery.

Prednisolone (Syrup 15mg/5ml) is an intermediate-acting synthetic glucocorticoid with four times the anti-inflammatory potency of hydrocortisone and minimal mineralocorticoid activity, on the WHO Model List of Essential Medicines. It diffuses across cell membranes and binds intracellular glucocorticoid receptors, inhibiting NF-kB, downregulating phospholipase A2, and potently suppressing synthesis of prostaglandins, leukotrienes, and pro-inflammatory cytokines. Indicated for severe autoimmune disorders (systemic lupus erythematosus, rheumatoid arthritis), acute asthma exacerbations, nephrotic syndrome, severe allergic reactions, inflammatory bowel disease, and immunosuppressive therapy.

Prednisolone (Dispersible Tablets 20mg) is an intermediate-acting synthetic glucocorticoid with four times the anti-inflammatory potency of hydrocortisone and minimal mineralocorticoid activity, on the WHO Model List of Essential Medicines. It diffuses across cell membranes and binds intracellular glucocorticoid receptors, inhibiting NF-kB, downregulating phospholipase A2, and potently suppressing synthesis of prostaglandins, leukotrienes, and pro-inflammatory cytokines. Indicated for severe autoimmune disorders (systemic lupus erythematosus, rheumatoid arthritis), acute asthma exacerbations, nephrotic syndrome, severe allergic reactions, inflammatory bowel disease, and immunosuppressive therapy.

Prednisolone (Tablets IP 5mg/10mg/40mg) is an intermediate-acting synthetic glucocorticoid with four times the anti-inflammatory potency of hydrocortisone and minimal mineralocorticoid activity, on the WHO Model List of Essential Medicines. It diffuses across cell membranes and binds intracellular glucocorticoid receptors, inhibiting NF-kB, downregulating phospholipase A2, and potently suppressing synthesis of prostaglandins, leukotrienes, and pro-inflammatory cytokines. Indicated for severe autoimmune disorders (systemic lupus erythematosus, rheumatoid arthritis), acute asthma exacerbations, nephrotic syndrome, severe allergic reactions, inflammatory bowel disease, and immunosuppressive therapy.